article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

FDA publishes more than 200 archived CRLs for transparency

Pharmaceutical Technology

By GlobalData Learn more about Strategic Intelligence A study conducted by FDA researchers in 2015 found that companies did not publicly acknowledge 85% of safety and efficacy concerns raised by the agency. Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA creates new priority review voucher scheme to boost US interests

Pharmaceutical Technology

In 2015, AbbVie spent $350m for a voucher to United Therapeutics, a market high, but voucher prices have gone down as more have become available for sale. A key incentive for those securing vouchers has been the ability to sell them to other pharma companies , with deals averaging around $100m in recent times, as per a GlobalData analysis.

FDA 59
article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Male yeast infection cream: Best antifungal treatments and how to use them

The Checkup by Singlecare

Without insurance coverage or coupons, brand-name Lotrimin can cost up to $149, although generic versions can be much cheaper. Even without insurance or other assistance, Monistat is generally pretty affordable; often around $14. And that price can decrease even more with insurance coverage or coupons.

article thumbnail

Bavarian Nordic nets $160m from priority review voucher sale

Pharmaceutical Technology

The record for the most expensive PRV occurred in 2015 when AbbVie bought a voucher from United Therapeutics for $350m. By GlobalData Learn more about Strategic Intelligence Sale figures increasing after dip PRVs were introduced in 2012 to incentivise development into non-lucrative disease areas.

FDA 52
article thumbnail

Planning, not panic, as BIO weighs in on US vaccination woes

pharmaphorum

Skip to main content Thursday 19 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)